Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis

The rapid expansion of psoriasis biologics has led to an urgent need to understand their relative efficacy and tolerability to inform treatment decisions better and, specifically, to inform guideline development.

[1]  L. Coates,et al.  British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update , 2020, The British journal of dermatology.

[2]  D. Shrom,et al.  Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. , 2019, Journal of the American Academy of Dermatology.

[3]  R. Burge,et al.  Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses , 2019, Dermatology and Therapy.

[4]  D. Stocken,et al.  Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis , 2019, JAMA dermatology.

[5]  Ruilian Li,et al.  Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trial , 2019, Journal of immunology research.

[6]  R. Emsley,et al.  Psoriasis treat to target: defining outcomes in psoriasis using data from a real‐world, population‐based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR) , 2019, British Journal of Dermatology.

[7]  A. Armstrong,et al.  Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial , 2019, The Lancet.

[8]  Jacqueline Pich.  Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. , 2019, International journal of evidence-based healthcare.

[9]  R. Warren,et al.  Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response , 2019, PloS one.

[10]  C. Curtis,et al.  HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. , 2019, The Journal of allergy and clinical immunology.

[11]  Yinglv Yu,et al.  Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis. , 2019, Journal of pharmacological sciences.

[12]  B. Strober,et al.  Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. , 2019, Journal of the American Academy of Dermatology.

[13]  D. Stocken,et al.  Defining the Therapeutic Range for Adalimumab and Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study , 2019, The Journal of investigative dermatology.

[14]  L. Levin,et al.  Long‐term efficacy of novel therapies in moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis of PASI response , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

[15]  N. Reynolds,et al.  Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR) , 2018, British Journal of Dermatology.

[16]  Jianhua Zhao,et al.  Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis , 2018, Experimental and therapeutic medicine.

[17]  T. Bhutani,et al.  A systematic review of active comparator controlled clinical trials in patients with moderate-to-severe psoriasis , 2018, The Journal of dermatological treatment.

[18]  J. Linder,et al.  Comparative effectiveness of targeted immunomodulators for the treatment of moderate‐to‐severe plaque psoriasis: A systematic review and network meta‐analysis , 2018, Journal of the American Academy of Dermatology.

[19]  Richard D Riley,et al.  Multivariate and network meta-analysis of multiple outcomes and multiple treatments: rationale, concepts, and examples , 2017, British Medical Journal.

[20]  L. Coates,et al.  British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017 , 2017, The British journal of dermatology.

[21]  A. Burden,et al.  Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis , 2017, The Journal of investigative dermatology.

[22]  F. Gómez-García,et al.  Short‐term efficacy and safety of new biological agents targeting the interleukin‐23–T helper 17 pathway for moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis , 2017, The British journal of dermatology.

[23]  S. Langan,et al.  Psoriasis and comorbid diseases: Epidemiology. , 2017, Journal of the American Academy of Dermatology.

[24]  S. John,et al.  A systematic review of worldwide epidemiology of psoriasis , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[25]  A. Kamath,et al.  Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies. , 2016, Drug discovery today. Technologies.

[26]  F. Capon,et al.  Update on psoriasis immunopathogenesis and targeted immunotherapy , 2015, Seminars in Immunopathology.

[27]  G. Jemec,et al.  A systematic literature review to compare quality of life in psoriasis with other chronic diseases using EQ-5D-derived utility values , 2015, Patient related outcome measures.

[28]  M. Parmar,et al.  More multiarm randomised trials of superiority are needed , 2014, The Lancet.

[29]  Panagiota Spyridonos,et al.  Graphical Tools for Network Meta-Analysis in STATA , 2013, PloS one.

[30]  A. Burden,et al.  The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectives , 2012, The British journal of dermatology.

[31]  Ian R. White,et al.  Multivariate Random-effects Meta-regression: Updates to Mvmeta , 2011 .